studies

la/mBC - HER2 positive, ... vs. HER2 inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsNeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.62 [0.30; 1.27] 0.62[0.30; 1.27]NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 201210%301NAnot evaluable deaths (OS) (extension)detailed resultsNeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.72 [0.41; 1.27] 0.72[0.41; 1.27]NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 201210%301NAnot evaluable events or deaths (EFS)detailed resultsNeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.78 [0.47; 1.29] 0.78[0.47; 1.29]NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 201210%301NAnot evaluable events or deaths (EFS) (extended)detailed resultsNeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.81 [0.52; 1.26] 0.81[0.52; 1.26]NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 201210%301NAnot evaluable pCR detailed resultsNeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 2.60 [1.49; 4.54] 2.60[1.49; 4.54]NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 201210%301NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-07-02 07:50 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 355,337,146,317 - treatments: 1308

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons